GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MariMed Inc (OTCPK:MRMD) » Definitions » Gross Margin %

MariMed (MariMed) Gross Margin % : 44.52% (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is MariMed Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. MariMed's Gross Profit for the three months ended in Dec. 2023 was $17.3 Mil. MariMed's Revenue for the three months ended in Dec. 2023 was $38.9 Mil. Therefore, MariMed's Gross Margin % for the quarter that ended in Dec. 2023 was 44.52%.

Warning Sign:

MariMed Inc gross margin has been in long-term decline. The average rate of decline per year is -4.6%.


The historical rank and industry rank for MariMed's Gross Margin % or its related term are showing as below:

MRMD' s Gross Margin % Range Over the Past 10 Years
Min: -115.91   Med: 51.14   Max: 65.9
Current: 44.36


During the past 13 years, the highest Gross Margin % of MariMed was 65.90%. The lowest was -115.91%. And the median was 51.14%.

MRMD's Gross Margin % is ranked worse than
54.75% of 990 companies
in the Drug Manufacturers industry
Industry Median: 46.8 vs MRMD: 44.36

MariMed had a gross margin of 44.52% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for MariMed was -4.60% per year.


MariMed Gross Margin % Historical Data

The historical data trend for MariMed's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MariMed Gross Margin % Chart

MariMed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.01 61.55 54.55 47.73 44.36

MariMed Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.13 44.76 44.84 43.40 44.52

Competitive Comparison of MariMed's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, MariMed's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MariMed's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MariMed's Gross Margin % distribution charts can be found below:

* The bar in red indicates where MariMed's Gross Margin % falls into.



MariMed Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

MariMed's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=65.9 / 148.598
=(Revenue - Cost of Goods Sold) / Revenue
=(148.598 - 82.679) / 148.598
=44.36 %

MariMed's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=17.3 / 38.899
=(Revenue - Cost of Goods Sold) / Revenue
=(38.899 - 21.582) / 38.899
=44.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


MariMed  (OTCPK:MRMD) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

MariMed had a gross margin of 44.52% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


MariMed Gross Margin % Related Terms

Thank you for viewing the detailed overview of MariMed's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


MariMed (MariMed) Business Description

Traded in Other Exchanges
Address
10 Oceana Way, Floor 2, Norwood, MA, USA, 02062
MariMed Inc is a multi-state operator in the United States cannabis industry. It develops, operates, manages, and optimizes regulatory-compliant facilities for the cultivation, production, and dispensing of medical and adult-use cannabis. MariMed also licenses its proprietary brands of cannabis products along with other top brands in domestic markets Sources of revenue are comprised of Product sales (retail and wholesale), Real estate rental income, Supply procurement, Management fees, and Licensing fees.
Executives
Jon R Levine 10 percent owner C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
Timothy Shaw officer: Chief Operating Officer C/O MARIMED INC, 10 OCEANA WAY, NORWOOD MA 02062
Kathleen Tucker director C/O 10 OCEANA WAY, 2ND FLOOR, NORWOOD MA 02062
Susan M. Villare officer: Chief Financial Officer C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
Selhub Eva M.d. director C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
David R Allen director C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
Thomas Kidrin director 11 ROYAL ROAD, BROOKLINE MA 02445
Edward J Gildea director C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
Jay Coleman director 310 EAST 46TH ST. APT 9 F, NEW YORK NY 10017
Robert N Fireman director 145 ROSEMARY ST. SUITE H-2, NEEDHAM MA 02494
Worlds.com, Inc. director, 10 percent owner, officer: PRESIDENT, CEO, other: TREASURER, SECRETARY 11 ROYAL ROAD, BROOKLINE MA 02445
Christopher John Ryan officer: CFO, VICE PRESIDENT 11 ROYAL RD, BROOKLINE MA 02445